The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
BeiGene AUS Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
21 result(s) found, displaying 1 to 10
-
Cancellation by sponsorRequested by Beigene Aus Pty Ltd
-
-
Australian Public Assessment Report (AusPAR)Brukinsa (zanubritinib) was approved to treat adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma, including patients with deletion 17p and/or TP53 mutation.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TEVIMBRA tislelizumab 100 mg/10 mL concentrated injection vial.
-
Australian Public Assessment Report (AusPAR)Tevimbra (tislelizumab) has been approved for the treatment of oesophageal squamous cell carcinoma and non-small cell lung cancer.
-
Prescription medicine decision summaryTevimbra (tislelizumab) has been approved for the treatment of patients with various types of oesophageal squamous cell carcinoma and non-small cell lung cancer.
-
Jul-2024Prescription medicine evaluationActive ingredient: tislelizumab.
-
-
Apr-2024Prescription medicine evaluationActive ingredient: tislelizumab.
-